Pre-meeting Session:
2. Vincent T. Andriole ID Board Review Course
Wednesday, October 19, 2011: 8:00 AM-5:00 PM
Room: 205ABC

Learning Objectives:

At the conclusion of the course, attendees will be able to:

  • discuss the most current diseases of travelers
  • assess updated trends in HIV care
  • discuss prevention and treatment of health care-acquired infections that are on the rise, including multiple-antibiotic resistant bacterial infections and Clostridium difficile-associated diarrhea

Target Audience: Infectious Diseases Physicians, Fellows-in-Training

Tracks: Global ID, Investigative ID, HIV, Pediatric ID, Adult ID

Moderators:  Rafael Campo, MD, University of Miami and Janet Gilsdorf, MD, University of Michigan Medical Center


8:00 AM
Update on GI Infections
John G. Bartlett, MD, FIDSA

8:35 AM
Controversies in the New IDSA Guidelines
Thomas Hooton, MD, FIDSA

9:10 AM
Gram-Negative Resistant Organisms
David Gilbert, MD, FIDSA

9:45 AM

10:00 AM
Fungal Infection Update
Liise-anne Pirofski, MD, FIDSA

10:35 AM
Update on Viral Infections
Gregory Storch, MD, FIDSA

11:10 AM
Transplant Infections
Nina Singh, MD

11:45 AM

12:45 PM
Micro Lab Diagnostic Update
Ellen Jo Baron, PhD, FIDSA

1:20 PM
HIV Update
Paul Sax, MD, FIDSA

1:55 PM
Travel Medicine
Naomi Aronson, MD, FIDSA

2:30 PM

2:45 PM
Non-Infectious Causes of Fever
Bennett Lorber, MD, DSc (hon), FIDSA, MACP

3:20 PM
CNS Infections
Allan Tunkel, MD, PhD, FIDSA

3:55 PM
Update on Mycobacterial Infections
Jeffrey Starke, MD, FIDSA

CME Credits: Maximum of 7.5 hours of Category 1 credit possible

ACPE Credits: This session is not eligible for CPE credit.

ACPE Number:


R. Campo, Gilead Sciences: Grant Investigator and Scientific Advisor, Consulting fee and Grant recipient
Pfizer: Grant Investigator, Grant recipient
Tibotec: Scientific Advisor, Consulting fee
Merck: Grant Investigator, Scientific Advisor and Wife is an employee and stockholder , Consulting fee, Grant recipient and Wife received salary and stock

J. Gilsdorf, None

D. Gilbert, achaogen: Consultant, Consulting fee
antiviral inc: Consultant, Consulting fee
merck: Consultant, Consulting fee

J. G. Bartlett, None

L. A. Pirofski, None

E. J. Baron, Cepheid: Employee, Salary and stock options
NanoMR: Scientific Advisor, Consulting fee
CLIAC: Board Member, per diem
MorphDesign: Consultant, Consulting fee
Providence-St. Joseph Hospital: Consultant, Consulting fee
Immunosciences: Scientific Advisor, stocks
OpGen: Scientific Advisor, Consulting fee

N. Aronson, None

T. Hooton, None

G. Storch, None

N. Singh, Pfizer: Grant Investigator, Research support
CSL Behring: Grant Investigator, Research support

B. Lorber, None

P. Sax, Abbott: Consultant, Consulting fee
BMS: Investigator and Scientific Advisor, Consulting fee and Research grant
Gilead: Investigator and Scientific Advisor, Consulting fee and Research grant
Merck: Investigator and Scientific Advisor, Consulting fee and Research grant
GSK: Consultant and Investigator, Consulting fee and Research grant
Tibotec: Investigator and Scientific Advisor, Consulting fee and Grant recipient

A. Tunkel, None

J. Starke, Hoffman La Roche: , Consulting fee

See more of: Pre-meeting Session

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.